BG98523A - Hla-limited cytotoxic t-lymphocytic (ctl) epitopes of the virus of hepatite b - Google Patents

Hla-limited cytotoxic t-lymphocytic (ctl) epitopes of the virus of hepatite b

Info

Publication number
BG98523A
BG98523A BG98523A BG9852394A BG98523A BG 98523 A BG98523 A BG 98523A BG 98523 A BG98523 A BG 98523A BG 9852394 A BG9852394 A BG 9852394A BG 98523 A BG98523 A BG 98523A
Authority
BG
Bulgaria
Prior art keywords
virus
hepatite
ctl
hla
lymphocytic
Prior art date
Application number
BG98523A
Other languages
Bulgarian (bg)
English (en)
Inventor
Maria Vitiello
Robert Chesnut
Original Assignee
Cytel Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cytel Corporation filed Critical Cytel Corporation
Publication of BG98523A publication Critical patent/BG98523A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Communicable Diseases (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BG98523A 1991-08-26 1994-02-22 Hla-limited cytotoxic t-lymphocytic (ctl) epitopes of the virus of hepatite b BG98523A (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US74956891A 1991-08-26 1991-08-26
US82768292A 1992-01-29 1992-01-29
US87449192A 1992-04-27 1992-04-27
PCT/US1992/007218 WO1993003764A1 (en) 1991-08-26 1992-08-26 Hla-restricted hepatitis b virus ctl epitopes

Publications (1)

Publication Number Publication Date
BG98523A true BG98523A (en) 1995-05-31

Family

ID=27419385

Family Applications (1)

Application Number Title Priority Date Filing Date
BG98523A BG98523A (en) 1991-08-26 1994-02-22 Hla-limited cytotoxic t-lymphocytic (ctl) epitopes of the virus of hepatite b

Country Status (16)

Country Link
EP (2) EP0534615B1 (xx)
JP (2) JP3738395B2 (xx)
AU (1) AU687725B2 (xx)
BG (1) BG98523A (xx)
CA (1) CA2115839C (xx)
CZ (1) CZ42794A3 (xx)
DE (1) DE69231621T2 (xx)
ES (1) ES2155060T3 (xx)
FI (1) FI940918A (xx)
GR (1) GR3035575T3 (xx)
HU (1) HUT68510A (xx)
IL (1) IL102964A0 (xx)
NO (1) NO940660L (xx)
NZ (2) NZ244103A (xx)
OA (1) OA09888A (xx)
WO (1) WO1993003764A1 (xx)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6322789B1 (en) 1991-08-26 2001-11-27 Epimmune, Inc. HLA-restricted hepatitis B virus CTL epitopes
US5780036A (en) * 1991-08-26 1998-07-14 The Scripps Research Institute Peptides for inducing cytotoxic T lymphocyte responses to hepattis B virus
US6607727B1 (en) 1991-08-26 2003-08-19 The Scripps Research Institute Peptides for inducing cytotoxic T lymphocyte responses to hepatitus B virus
US6419931B1 (en) * 1991-08-26 2002-07-16 Epimmune Inc. Compositions and methods for eliciting CTL immunity
US7611713B2 (en) 1993-03-05 2009-11-03 Pharmexa Inc. Inducing cellular immune responses to hepatitis B virus using peptide compositions
US6689363B1 (en) 1992-01-29 2004-02-10 Epimmune Inc. Inducing cellular immune responses to hepatitis B virus using peptide and nucleic acid compositions
US7252829B1 (en) 1998-06-17 2007-08-07 Idm Pharma, Inc. HLA binding peptides and their uses
US9340577B2 (en) 1992-08-07 2016-05-17 Epimmune Inc. HLA binding motifs and peptides and their uses
AU4998993A (en) * 1992-08-07 1994-03-03 Epimmune, Inc. Hla binding peptides and their uses
US6235288B1 (en) 1992-08-26 2001-05-22 The Scripps Research Institute Peptides for inducing cytotoxic T lymphocyte responses to hepatitis B virus
US9266930B1 (en) 1993-03-05 2016-02-23 Epimmune Inc. Inducing cellular immune responses to Plasmodium falciparum using peptide and nucleic acid compositions
ATE221387T1 (de) * 1993-04-27 2002-08-15 United Biomedical Inc Immunogene lhrh peptidkonstrukion und synthetische, universale immunstimulatoren als impfstoffe
US5759551A (en) * 1993-04-27 1998-06-02 United Biomedical, Inc. Immunogenic LHRH peptide constructs and synthetic universal immune stimulators for vaccines
US6413935B1 (en) 1993-09-14 2002-07-02 Epimmune Inc. Induction of immune response against desired determinants
CN1135181A (zh) * 1993-09-14 1996-11-06 Cytel有限公司 使用泛dr结合肽改变免疫应答
GB9325772D0 (en) * 1993-12-16 1994-02-16 Smithkline Beecham Biolog Novel compounds
US5686068A (en) * 1994-03-24 1997-11-11 Ludwig Institute For Cancer Research Isolated peptides derived from MAGE-2, cytolytic T cells specific to complexes of peptide and HLA-A2 molecules, and uses thereof
WO1998029442A1 (en) * 1996-12-30 1998-07-09 Innogenetics N.V. ANNEXIN V-BINDING POLYPEPTIDES DERIVED FROM HBsAg AND THEIR USES
ATE352556T1 (de) * 1997-04-11 2007-02-15 Sangstat Medical Corp Zytomodulierende lipophile peptide zur modulation der immunsystemaktivität und hemmung von entzündungen
US7105164B1 (en) 1998-04-07 2006-09-12 Sanofi Pasteur Limited HIV-specific cytotoxic T-cell responses
US20010019714A1 (en) * 1998-04-07 2001-09-06 Charles D. Y. Sia Hiv-specific cytotoxic t-cell responses
CU22871A1 (es) 1998-12-02 2003-10-21 Ct Ingenieria Genetica Biotech Formulaciones conteniendo partículas semejantes a virus como inmunopotenciadores por vía mucosal
JP4776131B2 (ja) 1999-11-18 2011-09-21 エピミューン インコーポレイテッド ヘテロクリティックアナログおよび関連方法
US7026443B1 (en) 1999-12-10 2006-04-11 Epimmune Inc. Inducing cellular immune responses to human Papillomavirus using peptide and nucleic acid compositions
US7462354B2 (en) 1999-12-28 2008-12-09 Pharmexa Inc. Method and system for optimizing minigenes and peptides encoded thereby
US7585844B2 (en) * 2004-04-21 2009-09-08 The University Of Chicago Myosin light chain kinase inhibitors and methods of use
US7943140B2 (en) * 2006-08-14 2011-05-17 Thymon, Llc Compositions and methods for the treatment and prophylaxis of multiple strains and subtypes of HIV-1
CN101568550B (zh) 2006-10-17 2012-12-26 肿瘤疗法科学股份有限公司 用于表达mphosph1或depdc1多肽的癌症的肽疫苗
US8877206B2 (en) 2007-03-22 2014-11-04 Pds Biotechnology Corporation Stimulation of an immune response by cationic lipids
EP2276495B1 (en) * 2008-04-17 2018-11-21 PDS Biotechnology Corporation Stimulation of an immune response by enantiomers of cationic lipids
EP2391635B1 (en) 2009-01-28 2017-04-26 Epimmune Inc. Pan-dr binding polypeptides and uses thereof
RU2555346C2 (ru) 2009-08-07 2015-07-10 Трансген Са Композиция для лечения инфекции вирусом гепатита в
US10076570B2 (en) 2009-08-07 2018-09-18 Transgene S.A. Composition for treating HBV infection
TWI575070B (zh) 2011-07-12 2017-03-21 傳斯堅公司 Ｈｂｖ聚合酶突變體
JP5564730B2 (ja) 2011-08-12 2014-08-06 オンコセラピー・サイエンス株式会社 Ｍｐｈｏｓｐｈ１ペプチドおよびそれを含むワクチン
JP6153526B2 (ja) * 2011-09-06 2017-06-28 エージェンシー フォー サイエンス，テクノロジー アンド リサーチ ポリペプチドワクチン
US20150250872A1 (en) 2012-09-21 2015-09-10 Frank Bedu-Addo Vaccine compositions and methods of use
US20140220056A1 (en) * 2013-02-05 2014-08-07 Nitto Denko Corporation Vaccine composition for transdermal administration
EP2762153A3 (en) * 2013-02-05 2015-04-01 Nitto Denko Corporation Vaccine composition for mucosal administration
RU2765574C2 (ru) 2015-08-12 2022-02-01 Онкотерапи Сайенс, Инк. Пептид, полученный из depdc1, и содержащая его вакцина
EP3347046B1 (en) * 2015-09-08 2022-10-19 Universität Zürich Compositions against cat allergy
SG10201913531PA (en) 2015-10-08 2020-03-30 Oncotherapy Science Inc Mphosph1-derived peptide, and vaccine including same
AU2016354590B2 (en) 2015-11-13 2023-11-23 Pds Biotechnology Corporation Lipids as synthetic vectors to enhance antigen processing and presentation ex-vivo in dendritic cell therapy
US20190328869A1 (en) 2016-10-10 2019-10-31 Transgene Sa Immunotherapeutic product and mdsc modulator combination therapy

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4935235A (en) * 1979-05-24 1990-06-19 The Regents Of The University Of California Non-passageable viruses
US5017558A (en) * 1980-01-14 1991-05-21 The Regents Of The University Of California Synthetic vaccine peptide epitomes of hepatitis B surface antigen
JPS60161999A (ja) * 1984-02-02 1985-08-23 Chemo Sero Therapeut Res Inst ペプチド
US4882145A (en) * 1986-12-09 1989-11-21 Scripps Clinic And Research Foundation T cell epitopes of the hepatitis B virus nucleocapsid protein
US4818527A (en) * 1986-12-09 1989-04-04 Scripps Clinic And Research Foundation T cell epitopes of the hepatitis B virus nucleocapsid protein
JPH03504975A (ja) * 1988-06-14 1991-10-31 セル―エスシーアイ　コーポレイション 異種官能性細胞免疫剤、それを含有するワクチン及びその使用方法
IT1238343B (it) * 1989-10-16 1993-07-13 Cesalpino Andrea Fond Procedimento per la preparazione di vaccini capaci di generare non solo la risposta immune dei linfociti t helper,ma anche un'efficace risposta di linfociti t citotossici,e vaccini con queste caratteristiche
EP0510054A1 (en) * 1990-01-05 1992-10-28 United Biomedical, Inc. Hiv-1 core protein fragments

Also Published As

Publication number Publication date
NO940660L (no) 1994-04-22
IL102964A0 (en) 1993-01-31
JP3586278B2 (ja) 2004-11-10
NZ270605A (en) 1997-07-27
FI940918A (fi) 1994-04-08
JP2004075693A (ja) 2004-03-11
EP0534615A3 (en) 1994-05-25
NO940660D0 (no) 1994-02-25
CA2115839C (en) 2010-06-01
HUT68510A (en) 1995-06-28
FI940918A0 (fi) 1994-02-25
CZ42794A3 (en) 1994-11-16
DE69231621T2 (de) 2001-05-31
AU2548792A (en) 1993-03-16
WO1993003764A1 (en) 1993-03-04
JPH06510051A (ja) 1994-11-10
CA2115839A1 (en) 1993-03-04
ES2155060T3 (es) 2001-05-01
DE69231621D1 (de) 2001-02-08
EP0534615B1 (en) 2001-01-03
OA09888A (en) 1994-09-15
EP1018344A3 (en) 2000-09-20
EP1018344A2 (en) 2000-07-12
GR3035575T3 (en) 2001-06-29
JP3738395B2 (ja) 2006-01-25
HU9400581D0 (en) 1994-05-30
NZ244103A (en) 1997-07-27
EP0534615A2 (en) 1993-03-31
AU687725B2 (en) 1998-03-05

Similar Documents

Publication Publication Date Title
BG98523A (en) Hla-limited cytotoxic t-lymphocytic (ctl) epitopes of the virus of hepatite b
ATE320493T1 (de) Modifizierung des hepatitis b kernantigens
RU94042722A (ru) Химерный белок, ген, клетка, вектор, способ получения химерного белка, вакцина
DK0610250T4 (da) Vaccine med porcint reproduktivt respiratorisk syndrom (PRRS) og diagnose heraf
YU48250B (sh) Postupak za pripremanje aktivne vakcine protiv lajmske bolesti
ATE402715T1 (de) Hcv-impfstoff zusammensetzungen
WO2006041866A3 (en) Prevention and treatment of hcv infection employing antibodies directed against conformational and linear epitopes
DE69327587D1 (de) Konjugate von schwach immunogenen antigenen und synthetischen peptidträgern und impfstoffe diese enthaltend
ATE97815T1 (de) Kombiniertes hepatitis a- und b-vakzin mit adjuvans.
NO940661L (no) Peptider for indusering av cytotoksisk T-lymfocytreaksjoner mot hepatit B virus
EA200300129A1 (ru) Очистка антигенов вируса гепатита b (hbv) для применения в вакцинах
Dezfuli et al. Induction of IFN-γ cytokine response against hepatitis B surface antigen using melittin
Mifune et al. Essential role of T cells in the postexposure prophylaxis of rabies in mice
Deresinski Concurrent Plasmodium vivax malaria and dengue
Yasaghi et al. Potentiation of human papilloma vaccine candidate using naloxone/alum mixture as an adjuvant: increasing immunogenicity of HPV-16E7d vaccine
WO2004005316A3 (en) Prevention and treatment of hcv infection employing antibodies directed against conformational and linear epitopes
NZ295056A (en) Hepatitis virus e strain, recombinant proteins thereof, use in diagnostic methods and vaccines
DE69420970D1 (de) Impfstoff zubereitungen
Pütz et al. The rationale of a peptide-conjugate vaccine against measles
Karl et al. Antibodies produced by rabbits immunized with visna virus
ATE409705T1 (de) Pre-s-protein von hepatitis-b-virus (hbv) als adjuvans und komponente eines hbv-impfstoffs
McLaren et al. Immunity to influenza in ferrets: XII. Immunization of ferrets with TNBP-split influenza virus vaccine
Inchauspe Protection and defence mechanisms in HCV infection
Portnyagina et al. Dynamics of immune response to porine from Yersinia pseudotuberculosis outer membrane
ATE249846T1 (de) Antivirale und antiretrovirale radioimmunpharmaka auf der basis von alpha- und beta-strahlern